The experimental Johnson & Johnson coronavirus vaccine entered human experiments this month after an initial study showed that it helped protect a group of primates with a single hit.
According to a study published in the medical journal Nature, all animals exposed to the pandemic six weeks after injection were immune, except for one that showed only low levels of the virus. The results prompted a healthcare company to begin human studies last week in Belgium and earlier this week in the US
“We are thrilled to see these preclinical data because they show that our SARS-CoV-2 vaccine candidate elicited a strong antibody response and provided single-dose protection,”; said Paul Stoffels, Johnson & Johnson’s chief scientist. “The findings give us confidence as we move in with vaccine development and increased production.”
The company said it was set to begin the final phase of testing in September and that 1,045 people would take part.
Johnson & Johnson is competing against several other companies fighting for the vaccine, and while other companies have evolved faster, the ability of Johnson & Johnson to produce an immune response in a single dose could give it an advantage in introducing the vaccine. vaccine.
The company did not announce the estimated price per shot, but said it was producing to try to provide more than a billion benefits to people around the world.